These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 30211730)

  • 21. TERT promoter mutations are frequent in cutaneous basal cell carcinoma and squamous cell carcinoma.
    Griewank KG; Murali R; Schilling B; Schimming T; Möller I; Moll I; Schwamborn M; Sucker A; Zimmer L; Schadendorf D; Hillen U
    PLoS One; 2013; 8(11):e80354. PubMed ID: 24260374
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fluorescence in situ hybridization analysis of atypical melanocytic proliferations and melanoma in young patients.
    DeMarchis EH; Swetter SM; Jennings CD; Kim J
    Pediatr Dermatol; 2014; 31(5):561-9. PubMed ID: 24924836
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnostic Distinction of Malignant Melanoma and Benign Nevi by a Gene Expression Signature and Correlation to Clinical Outcomes.
    Ko JS; Matharoo-Ball B; Billings SD; Thomson BJ; Tang JY; Sarin KY; Cai E; Kim J; Rock C; Kimbrell HZ; Flake DD; Warf MB; Nelson J; Davis T; Miller C; Rushton K; Hartman AR; Wenstrup RJ; Clarke LE
    Cancer Epidemiol Biomarkers Prev; 2017 Jul; 26(7):1107-1113. PubMed ID: 28377414
    [No Abstract]   [Full Text] [Related]  

  • 24. Distinguishing melanocytic nevi from melanoma by DNA copy number changes: comparative genomic hybridization as a research and diagnostic tool.
    Bauer J; Bastian BC
    Dermatol Ther; 2006; 19(1):40-9. PubMed ID: 16405569
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic impact and concordance of TERT promoter mutation and protein expression in matched primary and metastatic cutaneous melanoma.
    Hugdahl E; Kalvenes MB; Mannelqvist M; Ladstein RG; Akslen LA
    Br J Cancer; 2018 Jan; 118(1):98-105. PubMed ID: 29123258
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BRAF and NRAS mutations in melanoma and melanocytic nevi.
    Poynter JN; Elder JT; Fullen DR; Nair RP; Soengas MS; Johnson TM; Redman B; Thomas NE; Gruber SB
    Melanoma Res; 2006 Aug; 16(4):267-73. PubMed ID: 16845322
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapy.
    Thielmann CM; Matull J; Zaremba A; Murali R; Chorti E; Lodde G; Jansen P; Herbst R; Terheyden P; Utikal J; Pföhler C; Ulrich J; Kreuter A; Mohr P; Gutzmer R; Meier F; Dippel E; Weichenthal M; Kretz J; Möller I; Sucker A; Paschen A; Livingstone E; Zimmer L; Hadaschik E; Ugurel S; Schadendorf D; Griewank KG
    Eur J Cancer; 2022 Jan; 161():99-107. PubMed ID: 34936949
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic Background of Iris Melanomas and Iris Melanocytic Tumors of Uncertain Malignant Potential.
    van Poppelen NM; Vaarwater J; Mudhar HS; Sisley K; Rennie IG; Rundle P; Brands T; van den Bosch QCC; Mensink HW; de Klein A; Kiliç E; Verdijk RM
    Ophthalmology; 2018 Jun; 125(6):904-912. PubMed ID: 29371009
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of a novel noninvasive adhesive patch test for the evaluation of pigmented lesions of the skin.
    Gerami P; Alsobrook JP; Palmer TJ; Robin HS
    J Am Acad Dermatol; 2014 Aug; 71(2):237-44. PubMed ID: 24906614
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TERT promoter mutations are not always associated with poor prognosis in atypical spitzoid tumors.
    Requena C; Heidenreich B; Kumar R; Nagore E
    Pigment Cell Melanoma Res; 2017 Mar; 30(2):265-268. PubMed ID: 27930864
    [No Abstract]   [Full Text] [Related]  

  • 31. Coexistence of TERT promoter and BRAF mutations in cutaneous melanoma is associated with more clinicopathological features of aggressiveness.
    Macerola E; Loggini B; Giannini R; Garavello G; Giordano M; Proietti A; Niccoli C; Basolo F; Fontanini G
    Virchows Arch; 2015 Aug; 467(2):177-84. PubMed ID: 26055532
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of mutations in B-RAF, N-RAS, and H-RAS genes in the differential diagnosis of Spitz nevus and spitzoid melanoma.
    van Dijk MC; Bernsen MR; Ruiter DJ
    Am J Surg Pathol; 2005 Sep; 29(9):1145-51. PubMed ID: 16096402
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Telomerase Expression in a Series of Melanocytic Neoplasms.
    de Unamuno Bustos B; Sahuquillo Torralba A; Moles Poveda P; Pérez Simó G; Simarro Farinos J; Llavador Ros M; Palanca Suela S; Botella Estrada R
    Actas Dermosifiliogr (Engl Ed); 2019 Apr; 110(3):212-219. PubMed ID: 30591199
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical and Histopathologic Characteristics of Melanocytic Lesions on the Volar Skin Without Typical Dermoscopic Patterns.
    Mikoshiba Y; Minagawa A; Koga H; Yokokawa Y; Uhara H; Okuyama R
    JAMA Dermatol; 2019 May; 155(5):578-584. PubMed ID: 30865233
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potential diagnostic utility of PRAME and p16 immunohistochemistry in melanocytic nevi and malignant melanoma.
    Bahmad HF; Oh KS; Alexis J
    J Cutan Pathol; 2023 Aug; 50(8):763-772. PubMed ID: 37114299
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TERT and AURKA gene copy number gains enhance the detection of acral lentiginous melanomas by fluorescence in situ hybridization.
    Diaz A; Puig-Butillé JA; Valera A; Muñoz C; Costa D; Garcia-Herrera A; Carrera C; Sole F; Malvehy J; Puig S; Alos L
    J Mol Diagn; 2014 Mar; 16(2):198-206. PubMed ID: 24374110
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activation of mutant TERT promoter by RAS-ERK signaling is a key step in malignant progression of BRAF-mutant human melanomas.
    Li Y; Cheng HS; Chng WJ; Tergaonkar V
    Proc Natl Acad Sci U S A; 2016 Dec; 113(50):14402-14407. PubMed ID: 27911794
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lack of TERT promoter mutations in melanomas with extensive regression.
    de Unamuno Bustos B; Murria Estal R; Pérez Simó G; Oliver Martínez V; Llavador Ros M; Palanca Suela S; Botella Estrada R
    J Am Acad Dermatol; 2016 Mar; 74(3):570-2. PubMed ID: 26892657
    [No Abstract]   [Full Text] [Related]  

  • 39. Molecular profiling, including TERT promoter mutations, of acral lentiginous melanomas.
    Vazquez Vde L; Vicente AL; Carloni A; Berardinelli G; Soares P; Scapulatempo C; Martinho O; Reis RM
    Melanoma Res; 2016 Apr; 26(2):93-9. PubMed ID: 26709572
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnosis of cutaneous melanocytic tumours by four-colour fluorescence in situ hybridisation.
    Morey AL; Murali R; McCarthy SW; Mann GJ; Scolyer RA
    Pathology; 2009; 41(4):383-7. PubMed ID: 19404853
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.